Bluelinea raises €5.32M in APICIL-backed lifeline as sales slide
What's the deal? French teleassistance company BluelineaDealroom has a profile for this one. Try Dealroom → has completed a €5.32 million capital increase, issuing 106,432,512 new shares at €0.05 each. The raise was backed in full by majority shareholder APICIL GroupDealroom has a profile for this one. Try Dealroom →, which now holds 92.15% of the share capital and 91.82% of voting rights.
Why now? Bluelinea's 2026 trading has deteriorated sharply: revenue fell 12% in the first half and 19% in the third quarter, while first-half EBITDA swung to a loss. The company has pointed to cautious customers and the costly transition away from 2G devices.
What's the endgame? This is a balance-sheet rescue, not a growth round. Net proceeds of roughly €5.2 million will repay about €1.9 million of debt and cover operating needs, buying the company what it says is 18 months of continuity.
What could go wrong? The raise follows a €1.5 million issue in July, and the heavy dilution is stark — a shareholder who held 1% before the deal now retains just 0.20%. Repeated fundraising signals that stabilising the business, not expanding it, remains the core challenge.
The signal: Bluelinea operates in the French Silver Economy, serving seniors — a sector often framed as a growth story. Its back-to-back rescue raises show that demographic tailwinds alone don't guarantee a healthy balance sheet, and that survival here now depends on a single committed backer.
Read more: webdisclosure.com
Image credit: agilemktg1
